Who are Desoxyn's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Strattera, Propadrine, Edronax, Rilutek, Fenmetrazina, Sanorex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methamphetamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Desoxyn — Competitive Intelligence Brief

Desoxyn (METHAMPHETAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amphetamine Anorectic. Area: Metabolic.

marketed Amphetamine Anorectic Sodium-dependent noradrenaline transporter Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Desoxyn (METHAMPHETAMINE) — Ajenat Pharms. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Desoxyn TARGET	METHAMPHETAMINE	Ajenat Pharms	marketed	Amphetamine Anorectic	Sodium-dependent noradrenaline transporter	1943-01-01
Strattera	ATOMOXETINE	Eli Lilly	marketed	Norepinephrine Reuptake Inhibitor	Sodium-dependent noradrenaline transporter	2002-01-01
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	marketed	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Edronax	REBOXETINE		marketed	reboxetine	Sodium-dependent noradrenaline transporter	1997-01-01
Rilutek	RILUZOLE	Covis	marketed	Benzothiazole [EPC]	Sodium-dependent noradrenaline transporter	1995-01-01
Fenmetrazina	PHENMETRAZINE	Boehringer Ingelheim	marketed	phenmetrazine	Sodium-dependent noradrenaline transporter	1982-01-01
Sanorex	MAZINDOL		marketed	mazindol	Sodium-dependent noradrenaline transporter	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-03-12 — Rilutek · 8765150 · Formulation · US

Sponsor landscape (Amphetamine Anorectic class)

Ajenat Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Desoxyn — Competitive Intelligence Brief. https://druglandscape.com/ci/methamphetamine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab